Penile calciphylaxis: A retrospective case-control study - 12/10/21
Abstract |
Background |
Calciphylaxis is a rare disorder characterized by skin necrosis caused by calcium deposition within vessels, thrombosis, and subsequent tissue ischemia. Penile involvement may rarely occur.
Objective |
To identify risk factors, diagnosis, management, and mortality of patients with penile calciphylaxis.
Methods |
A retrospective medical record review was conducted of 16 patients with penile calciphylaxis treated at 2 large urban tertiary care centers between January 2001 and December 2019. A control group of 44 male patients with nonpenile calciphylaxis at the same institution was included.
Results |
The median survival of patients with penile calciphylaxis was 3.8 months (interquartile range, 27.0 months). Mortality was 50% at 3 months and 62.5% at 6 months for penile calciphylaxis, and 13.6% at 3 months and 29.5% at 6 months for controls (P = .008). Patients with penile calciphylaxis were less likely to be obese (P = .04) but more likely to have hyperparathyroidism (P = .0003) and end-stage renal disease (P = .049).
Limitations |
Retrospective study design and small sample size.
Conclusions |
This study further defines the disease course of penile calciphylaxis, which has high mortality. Imaging may be used to aid diagnosis. Risk factors include end-stage renal disease, hyperparathyroidism, and normal body mass index.
Le texte complet de cet article est disponible en PDF.Key words : calciphylaxis, diagnosis, management, outcomes, penile, risk factors
Abbreviations used : ESRD, STS
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Nigwekar has received grant support from Hope Pharmaceuticals. Authors Gabel, Chakrala, and Nguyen and Drs Shah, Danesh, Dobry, Garza-Mayers, Ko, St. John, Walls, Song, and Kroshinsky have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved by Partners Institutional Review Board: 2018P000551 |
Vol 85 - N° 5
P. 1209-1217 - novembre 2021 Retour au numéro
Article précédent
- Complete and transparent reporting of primary end points of randomized trials in the dermatology literature: A comparison of registered and published primary end points
- Do-Yeop Kim, Sohee Oh, Hyun-Sun Yoon
- Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017
- Shayan Cheraghlou, Kalman L. Watsky, Jeffrey M. Cohen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?